TESS V3 Modular Total Shoulder System PMCF
← catalyst calendarSponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
67actual
Sites
2
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Termination of PMCF study due to product discontinuation (commercial reasons)
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-01 | actual | When the study began enrolling |
| Primary completion | 2026-03-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-05 | actual | The whole study's end, after follow-up |
| First posted | 2021-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteoarthritis Shoulder
- Rheumatoid Arthritis
- Rheumatoid Arthritis Shoulder
- Avascular Necrosis
- Revision
- Rotator Cuff Tears
- Osteonecrosis
- Rotator Cuff Tear Arthropathy
- Proximal Humeral Fracture
- Malunion of Fracture, Shoulder Region
Interventions
- Device: Anatomic TESS V3
- Device: Reverse TESS V3
Primary outcomes
what the primary-completion date above is the date OFImplant survival at 10 years
measured 10 years
Frequency and incidence of adverse events
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed